Compare Amphastar Pharmaceuticals Inc (AMPH) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Vanguard Total Stock Market Index Fund ETF trades at $372.01. The key difference: Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | VTI | |
|---|---|---|
Market Cap | $826.08M | — |
Sector | Health | — |
52-Week High | $30.81 | $374.36 |
52-Week Low | $16.87 | $305.74 |
Enterprise Value | $1.22B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
VTI trades at $372.69, up 0.33% with a bullish technical signal from moving averages. The ETF provides diversified exposure to the entire U.S. stock market with over 3,400 holdings. Recent news highlights VTI's historical 10% annual returns and its inclusion in new tax-advantaged investment accounts. Technical indicators show support at $369 and resistance at $373, with RSI levels in neutral territory suggesting balanced momentum.
VTI offers broad market diversification at minimal cost (0.03% expense ratio), making it attractive for long-term investors. Key risks include market-wide volatility and economic uncertainty. Analyst sentiment remains positive given VTI's comprehensive exposure and low-cost structure, though investors should monitor broader economic indicators that could impact overall market performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
